Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Current Deferred Revenue (2020 - 2022)

Historic Current Deferred Revenue for Solid Biosciences (SLDB) over the last 3 years, with Q1 2022 value amounting to $6.2 million.

  • Solid Biosciences' Current Deferred Revenue fell 4213.09% to $6.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $6.2 million, marking a year-over-year decrease of 4213.09%. This contributed to the annual value of $8.1 million for FY2021, which is 6100.01% down from last year.
  • Latest data reveals that Solid Biosciences reported Current Deferred Revenue of $6.2 million as of Q1 2022, which was down 4213.09% from $8.1 million recorded in Q4 2021.
  • In the past 5 years, Solid Biosciences' Current Deferred Revenue registered a high of $20.7 million during Q4 2020, and its lowest value of $6.2 million during Q1 2022.
  • In the last 3 years, Solid Biosciences' Current Deferred Revenue had a median value of $9.5 million in 2021 and averaged $10.8 million.
  • As far as peak fluctuations go, Solid Biosciences' Current Deferred Revenue plummeted by 6100.01% in 2021, and later plummeted by 4213.09% in 2022.
  • Quarter analysis of 3 years shows Solid Biosciences' Current Deferred Revenue stood at $20.7 million in 2020, then plummeted by 61.0% to $8.1 million in 2021, then fell by 23.64% to $6.2 million in 2022.
  • Its Current Deferred Revenue stands at $6.2 million for Q1 2022, versus $8.1 million for Q4 2021 and $8.9 million for Q3 2021.